Voyager Therapeutics (VYGR) Depreciation & Amortization (CF) (2014 - 2026)

Voyager Therapeutics has disclosed Depreciation & Amortization (CF) across 13 years of filings, most recently posting $932000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $932000.0, down 8.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (down 11.07% YoY), and the FY2025 annual result was $4.1 million, down 12.77% from the prior year.
• Depreciation & Amortization (CF) came in at $932000.0 for Q1 2026 at Voyager Therapeutics, down from $1.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.8 million in Q1 2022 to a low of $834000.0 in Q4 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.1 million (2023), against an average of $1.2 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 120.72% in 2022 and slumped 61.77% in 2023, its largest moves.
• Voyager Therapeutics' Depreciation & Amortization (CF) stood at $834000.0 in 2022, then soared by 60.07% to $1.3 million in 2023, then decreased by 26.59% to $980000.0 in 2024, then grew by 11.12% to $1.1 million in 2025, then declined by 14.42% to $932000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $932000.0 (Q1 2026), $1.1 million (Q4 2025), and $932000.0 (Q3 2025), per Business Quant data.